Trial Profile
A Phase II, Open-label, Single-arm, Multi-cohort, Proof-of-principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
- Indications Adenocarcinoma; Appendiceal cancer; Colorectal cancer; Skin tumours; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- 04 Apr 2024 Status changed from active, no longer recruiting to completed.
- 20 Dec 2023 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.
- 20 Dec 2023 Planned primary completion date changed from 31 Jan 2024 to 31 Jan 2025.